The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc. is $16.00, about 46.3% above its August 10 closing price of $10.94
The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 14 three months ago
Outlook and growth drivers
Company expects cash and projected PEDMARK revenues to fund operations based on the current plan
Fennec Pharmaceuticals sees continued commercial momentum for PEDMARK into the third quarter
Company expects sales organization expansion to support further commercial growth
Commercial expansion - Co said expansion of the commercial organization and increased engagement with healthcare providers drove unprecedented PEDMARK enrollment and sales growth
- Co attributed sales growth to increased demand from new accounts, especially in the AYA population
FENC•
